Acquisition by Bioprojet of a new molecule for the treatment of narcolepsy

A new molecule to treat sleep disorders | Bioprojet | Paris

Breaking News !
We are delighted to announce an exclusive and worldwide acquisition by Bioprojet, in partnership with Harmony Biosciences, of a new molecule for the treatment of narcolepsy and other sleep/wake disorders.

TPM-1116 is a new highly potent and selective oral orexin-2 receptor (OX2R) agonist discovered by Teijin Pharma Limited, a Japanese pharmaceutical group. Thanks to this innovative molecule currently undergoing pre-clinical development, we look forward to
continue improving the quality of life of patients living with narcolepsy.

This exciting acquisition is a new chapter in Bioprojet’s history, and an opportunity to renew our commitment to helping patients by offering new, innovative and first-in-class treatments.

We would like to express our gratitude to all individuals involved in this fruitful collaboration, which contributes to enriching our R&D portfolio and addressing pressing medical needs in a field we are familiar with.